Web of Science: 33 cites, Scopus: 40 cites, Google Scholar: cites
Packaging protein drugs as bacterial inclusion bodies for therapeutic applications
Villaverde Corrales, Antonio (Universitat Autònoma de Barcelona. Departament de Genètica i de Microbiologia)
García Fruitós, Elena (Universitat Autònoma de Barcelona. Departament de Genètica i de Microbiologia)
Rinas, Ursula (Helmholtz-Zentrum für Infektionsforschung)
Seras Franzoso, Joaquin (Universitat Autònoma de Barcelona. Departament de Genètica i de Microbiologia)
Kosoy, Ana (Janus Development SL)
Corchero Nieto, José Luis (Universitat Autònoma de Barcelona. Departament de Genètica i de Microbiologia)
Vázquez, Esther (Universitat Autònoma de Barcelona. Departament de Genètica i de Microbiologia)
Institut de Biotecnologia i de Biomedicina

Data: 2012
Resum: A growing number of insights on the biology of bacterial inclusion bodies (IBs) have revealed intriguing utilities of these protein particles. Since they combine mechanical stability and protein functionality, IBs have been already exploited in biocatalysis and explored for bottom-up topographical modification in tissue engineering. Being fully biocompatible and with tuneable bio-physical properties, IBs are currently emerging as agents for protein delivery into mammalian cells in protein-replacement cell therapies. So far, IBs formed by chaperones (heat shock protein 70, Hsp70), enzymes (catalase and dihydrofolate reductase), grow factors (leukemia inhibitory factor, LIF) and structural proteins (the cytoskeleton keratin 14) have been shown to rescue exposed cells from a spectrum of stresses and restore cell functions in absence of cytotoxicity. The natural penetrability of IBs into mammalian cells (reaching both cytoplasm and nucleus) empowers them as an unexpected platform for the controlled delivery of essentially any therapeutic polypeptide. Production of protein drugs by biopharma has been traditionally challenged by IB formation. However, a time might have arrived in which recombinant bacteria are to be engineered for the controlled packaging of therapeutic proteins as nanoparticulate materials (nanopills), for their extra- or intra-cellular release in medicine and cosmetics.
Nota: Altres ajuts: A. Villaverde has been granted with an ICREA ACADEMIA award (from ICREA, Catalonia, Spain) and EGF is supported by the Programa Personal de Técnico de Apoyo (Modalidad Infraestructuras científco-tecnológicas, MICINN). JSF is a PIF fellowship holder from UAB, Spain.
Nota: Número d'acord de subvenció MICINN/BFU2010-17450
Nota: Número d'acord de subvenció AGAUR/2009/SGR-108
Drets: Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l’obra i la creació d’obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l’autoria de l’obra original. Creative Commons
Llengua: Anglès.
Document: article ; recerca ; publishedVersion
Publicat a: Microbial cell factories, Vol. 11 (June 2012) , art. 76, ISSN 1475-2859

PMID: 22686540
DOI: 10.1186/1475-2859-11-76


5 p, 470.7 KB

El registre apareix a les col·leccions:
Articles > Articles de recerca
Articles > Articles publicats

 Registre creat el 2018-01-26, darrera modificació el 2018-11-14



   Favorit i Compartir